Xenon MRI scans to study lung blood vessels in pulmonary hypertension
Tests inhaled xenon MRI scans in adults with pulmonary arterial hypertension.
Plain-language title generated from the registry record
Registry title: Xenon MRI Pulm Hypertension
Key facts
- Where
- Durham, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT04991454, who can take part
Where in United States
- Duke University Medical CenterDurham, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bastiaan Driehuys
- Trial code
- NCT04991454
- Record updated
- 10 August 2026
- Original description
The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.Read full original descriptionShow less
Xenon MRI in Pulmonary Hypertension
The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.
Inclusion: Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:; Outpatients of either gender, Age 18-75; Awaiting a lung transplant; Diagnosis of precapillary PH (right heart catheterization demonstrating hemodynamic criteria of a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg, pulmonary vascular resistance ≥ 3 WU, pulmonary capillary wedge pressure ≤ 15 mmHg) in the setting of Group 1 (PAH), 3 (PH due to chronic lung disease, 4 (PH due to pulmonary artery obstructions), or 5 (PH due to miscellaneous causes); Willing and giving informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed); Women of childbearing potential must have a negative urine pregnancy test before MRI; Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:; Treatment naïve or treatment started within the last 3 months; Outpatients of either gender, Age 18-75; WHO functional class (FC) 2-3 symptoms with a diagnosis of group 1 PH (mean pulmonary artery pressures (mPAP) > 20 mmHg, pulmonary capillary wedge pressure (PCWP) ≤ 15mmHg and pulmonary vascular resistance (PVR) ≥3 WU); Willing and able to give informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed); Women of childbearing potential must have a negative urine pregnancy test before MRI.
Exclusion: Active cancer; Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine); Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements; Active cancer; Liver disease (Childs-Pugh class C); Any conditions that prevent the performance of 129Xe MRI scans; Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine); Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements; Moderate to severe heart disease (LVEF <45%, Severe LV hypertrophy, Moderate to severe valvular disease); Subjects presenting with any of the following will not be included in the trials:; PH due to schistosomiasis; Sickle cell anemia; Prisoners and pregnant women will not be approached for the study; Subjects presenting with any of the following will not be included in the trials:; Sarcoidosis; Sickle cell anemia; Prisoners and pregnant women will not be approached for the study.